Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Diabetes complications and comorbidities: Nephropathy

medwireNews top story

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

medwireNews top story

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

medwireNews top story

FIDELIO-DKD: Finerenone offers new treatment option for diabetic CKD

The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.

Featured podcast

EASD 2020: Editorial Board conference highlights

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting (39:05). 

EASD 2020

DAPA-CKD trial: Renal benefits of SGLT2 inhibition in people with and without diabetes

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).

EASD 2020 News

Further VERTIS-CV analysis supports ertugliflozin renal benefits

The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.

medwireNews top story

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

medwireNews top story

DAPA-CKD shows dapagliflozin benefits regardless of diabetes

The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.

medwireNews top story

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

medwireNews top story

Prediabetes marks increased vascular risk

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

View all highlights

medwireNews

04-09-2023 | Type 2 diabetes | News

New model predicts kidney disease progression risk in type 2 diabetes

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

22-06-2023 | Cardiovascular outcomes | News

Finerenone modifies CKD-associated CV risk in albuminuric type 2 diabetes

Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

26-05-2023 | Type 2 diabetes | News

Common antidiabetic add-on therapies offer similar renal outcomes

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

View all related news


More on diabetes complications and comorbidities

« Back to main page | Bone health | Cardiovascular disease | Depression | Diabetes distress | Diabetic foot | Gastrointestinal disorders | Hyperglycemia | Hyperglycemic hyperosmolar state | Hypoglycemia | Ketoacidosis | Macular edema | Mental health | Nephropathy | Neuropathy | Non-alcoholic fatty liver disease | Osteoporosis | Retinopathy | Sexual dysfunction | Sleep disorders | Specific populations | Type 1 diabetes | Type 2 diabetes


Interactive patient case study

21-12-2018 | Ketoacidosis | Case study | Link

Renal complications in diabetic ketoacidosis

Develop and test your knowledge on the renal complications associated with diabetic ketoacidosis through this practical example and self-assessment authored by Professor Francesco Chiarelli. This 15-minute case presents likely causes of renal complications in diabetic ketoacidosis and explains how to identify the signs and symptoms of renal complications to ensure early initiation of appropriate treatment.

View more interactive case studies

Themed collections

25-06-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

View all themed collections

Journal articles and book chapters

28-11-2018 | Cardiovascular disorders | Article

Serum uromodulin predicts less coronary artery calcification and diabetic kidney disease over 12 years in adults with type 1 diabetes: The CACTI study

Bjornstad P et al. Diabetes Care 2018: dc181527. doi: 10.2337/dc18-152

08-11-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

06-11-2018 | Nephropathy | Article

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): A randomized, placebo-controlled, phase 2 trial

de Zeeuw D et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30289-4

23-10-2018 | Complications | Article

Validation of time in range as an outcome measure for diabetes clinical trials

Beck RW et al. Diabetes Care 2018: dc181444. doi: 10.2337/dc18-1444

08-09-2018 | Nephropathy | Review | Article

Metabolic abnormalities in diabetes and kidney disease: Role of uremic toxins

Koppe L, Fouque D, Soulage CO. Curr Diab Rep 2018; 18: 97. doi: 10.1007/s11892-018-1064-7

15-08-2018 | Nephropathy | Review | Article

Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis

Iyengar R, Franzese J, Gianchandani R. Curr Diab Rep 2018; 18: 75. doi: 10.1007/s11892-018-1044-y

View all journal articles and book chapters

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

View all

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

View all
Image Credits